E. Huey

Symptom-Guided Blood Biomarker Testing for Alzheimer's Disease.

Technology‐natives and technology‐adopters: Age differences in remote cognitive assessment in Alzheimer disease

Cognitive changes in the asymptomatic stages of Alzheimer disease (AD) are subtle and difficult to detect using conventional cognitive tests. High‐frequency smartphone‐based testing may improve sensitivity to these changes, but generational differences in technology use could influence performance. We examined generati...

Smartphone Passive Digital Phenotyping in Frontotemporal Lobar Degeneration

Introduction: Frontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. Remote monitoring via low-burden digital health tools may overcome these barriers. We evaluated clinical utility...

The United States CADASIL Consortium: Baseline Findings from a Natural History Study

Conceptualizing cognition and behaviour across amyotrophic lateral sclerosis and frontotemporal dementia.

Cognitive and behavioral dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioral impairment (MBI), and into a clinically manifest stage recognized by...

Progress towards a biotypic biomarker profile for amyotrophic lateral sclerosis-frontotemporal spectrum disorders.

An international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for the detection of either ALS or FTD pathobiology prior to phenoconversion and/or predict phenoconversion in at risk individuals.

Discordance Between Genetic Ancestry and Self-Reported Race Impacts Inference of Neuropsychiatric Burden in Alzheimer's Disease

Genetically defined ancestry alters NPS prevalence estimates in AD, suggesting that standard race categories obscure population-level disease burden and compromise risk stratification, screening, and trial design.

Cerebrospinal fluid YWHAG:NPTX2 ratio predicts clinical severity and future phenoconversion in frontotemporal lobar degeneration

Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...